(0.24%) 5 535.00 points
(0.18%) 39 540 points
(0.26%) 19 979 points
(0.54%) $81.98
(-1.96%) $2.55
(0.23%) $2 344.90
(0.22%) $29.63
(-1.80%) $995.80
(-0.25%) $0.931
(-0.22%) $10.65
(-0.13%) $0.790
(1.96%) $87.40
Live Chart Being Loaded With Signals
Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer...
Stats | |
---|---|
今日成交量 | 166 670 |
平均成交量 | 182 962 |
市值 | 3.40B |
EPS | $-0.820 ( Q1 | 2024-03-31 ) |
下一个收益日期 | ( $-0.280 ) 2024-09-04 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E |
-5.85 (Sector) 42.63 (Industry) 30.78 |
ATR14 | $0.00700 (0.06%) |
音量 相关性
Alvotech 相关性 - 货币/商品
Alvotech 财务报表
Annual | 2023 |
营收: | $91.43M |
毛利润: | $-69.42M (-75.93 %) |
EPS: | $-2.43 |
FY | 2023 |
营收: | $91.43M |
毛利润: | $-69.42M (-75.93 %) |
EPS: | $-2.43 |
FY | 2023 |
营收: | $0 |
毛利润: | $0 (0.00 %) |
EPS: | $0 |
FY | 2022 |
营收: | $83.03M |
毛利润: | $18.93M (22.80 %) |
EPS: | $-2.60 |
Financial Reports:
No articles found.
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Alvotech
Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company\'s lead program is AVT02, a high concentration formulation biosimilar to Humira to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, Crohn\'s disease, ulcerative colitis, plaque psoriasis, and other indications; AVT04, a biosimilar to Stelara to treat various inflammatory conditions comprising psoriatic arthritis, Crohn\'s disease, ulcerative colitis, plaque psoriasis, and other indications; AVT06, a biosimilar to Eylea to treat various conditions, such as age-related macular degeneration, macular edema, and diabetic retinopathy; and AVT03, a biosimilar to Xgeva and Prolia, which is in the pre-clinical phase to treat prevent bone fracture, spinal cord compression, and the need for radiation or bone surgery in patients with certain types of cancer, as well as prevent bone loss and increase bone mass. It also offers AVT05, a biosimilar to Simponi and Simponi Aria, which is in early phase development to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, and other indications; AVT16, a biosimilar to an immunology product; AVT23, a biosimilar to Xolair, which is in late-stage development to treat nasal polyps; and AVT33, a biosimilar to an oncology product. The company was founded in 2013 and is headquartered in Reykjavik, Iceland.
关于 实时信号
此页面上呈现的实时信号有助于确定何时购买或出售NA. 信号具有高达1分钟的延迟;与所有市场信号一样,存在误差或错误的可能性。
实时交易信号不是绝对的,getagraph.com 对基于这些信号采取的任何行动概不负责,如《使用条款》中所述。这些信号是基于广泛的技术分析指标。